{"id":945304,"date":"2026-03-18T08:05:04","date_gmt":"2026-03-18T12:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/"},"modified":"2026-03-18T08:05:04","modified_gmt":"2026-03-18T12:05:04","slug":"arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/","title":{"rendered":"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WESTLAKE VILLAGE, Calif., and DENVER, March  18, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gX2IUo5H7LIV0ui-bqYe8tIiUH5K-AQdZP26HdjcyfgbCskwKlZNFfEZWNCHz-WpNOu8CNBW_4036k6v-7xBcBFV1AFpJwaShfXuFeTgGr8=\" rel=\"nofollow\" target=\"_blank\"><u>Arcutis Biotherapeutics, Inc.<\/u><\/a>\u00a0(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE<sup>\u00ae<\/sup> (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting\u00a0taking place March 27-31 in Denver.<\/p>\n<p>In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, building on recently announced topline data. In addition, a five-minute poster presentation will highlight long-term caregiver-reported outcomes from its INTEGUMENT-OLE Phase 3 trial of ZORYVE cream 0.05% in children aged 2 to 5 years with mild to moderate atopic dermatitis. Additional results will be presented in two e-posters from a STRATUM Phase 3 trial subgroup analysis in individuals with seborrheic dermatitis with face and scalp involvement, and Psoriasis Area and Severity Index (PASI) outcomes from the Phase 3 DERMIS-1\/2 and ARRECTOR trials in individuals with plaque psoriasis.<\/p>\n<p>\u201cThis year\u2019s AAD presentations reflect the continued momentum of our clinical development program and the expanding body of evidence supporting the value of ZORYVE across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis,\u201d said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. \u201cWe are particularly excited to share new results from the INTEGUMENT\u2011INFANT trial evaluating investigational ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, with its inclusion as a late\u2011breaking session underscoring the need for additional therapeutic options for this underserved pediatric age group.\u201d<\/p>\n<p>\n        <strong>Details of the presentations are as follows:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Podium: INTEGUMENT-INFANT: Once-Daily Roflumilast Cream 0.05% in Infants Aged 3\u2013&lt;24 Months With Atopic Dermatitis<\/strong><br \/>\n          <br \/>Abstract: #79891<br \/>Presenter: Lawrence F. Eichenfield, MD<br \/>Late-Breaking Session 1<br \/>Date: Saturday, March 28<br \/>Time: 10:12\u201310:24 a.m. MDT<br \/>Location: Bellco Theatre 3<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>5-minute Poster Presentation:<\/strong><br \/>\n          <strong>Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% in Caregiver-Reported Outcomes: Long-Term Results for Patients Aged 2\u20135 Years With Mild to Moderate Atopic Dermatitis in the INTEGUMENT-OLE Trial<\/strong><br \/>\n          <br \/>Presenter: Lawrence F. Eichenfield, MD<br \/>Date: Friday, March 27<br \/>Time: 4:25\u20134:30 p.m. MDT<br \/>Location: Lobby C, Poster Center 1<\/li>\n<\/ul>\n<p>\n        <strong>Poster Presentations<\/strong><br \/>\n        <br \/>The following posters will be available electronically at the conference beginning Friday, March 27:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>E-Poster:<\/strong> Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis: Subgroup Analysis of Patients With Involvement of the Face and\/or Scalp in the STRATUM Trial<br \/>Lead Author: Laura Ferris, MD<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>E-Poster:<\/strong> Roflumilast Cream 0.3% and Foam 0.3% in Psoriasis Area and Severity Index (PASI) Across Body Regions and Clinical Signs for Patients With Plaque Psoriasis<br \/>Lead Author: Melinda Gooderham, MD<\/li>\n<\/ul>\n<p>\n        <strong>About ZORYVE<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> (roflumilast)<\/strong><br \/>\n        <br \/>ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.\u00a0ZORYVE cream is a topical formulation of roflumilast, an advanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor. Inhibiting PDE4, an intracellular enzyme that is an established target in dermatology, decreases the production of pro-inflammatory mediators. This decreases inflammation in the skin and balances the skin\u2019s immune system.<\/p>\n<p>Demonstrating both clinical impact and broad industry recognition, ZORYVE has been honored with multiple prestigious awards and recommendations. ZORYVE was awarded by <em>Allure<\/em>\u00a0with the &#8220;2025 Best of Beauty Breakthrough Award,&#8221; making it the first FDA-approved medication for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis to win this prominent award. ZORYVE cream 0.3% and ZORYVE foam 0.3% were also awarded the National Psoriasis Foundation\u2019s Seal of Recognition\u2014the first FDA-approved prescription brand to receive the honor.\u00a0Additionally, the American Academy of Dermatology (AAD) issued a strong recommendation for the use of ZORYVE cream 0.15% in adult patients with mild to moderate atopic dermatitis, according to updated guidelines released in June 2025. In 2024, ZORYVE cream 0.15% was awarded\u00a0<em>Glamour\u2019s<\/em>\u00a0Beauty and Wellness Award for \u201cBest Eczema Product.\u201d<\/p>\n<p>\n        <strong>About Arcutis<\/strong><br \/>\n        <br \/>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis\u2019 unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xjBvZwagraDCYTIh4G7xoMXNdZUMeriJfwHrMGT9jcaP-EP3fLlfWRvwkjhj2qJJuWfxG3moD2tpozRdX8Lx6g==\" rel=\"nofollow\" target=\"_blank\">www.arcutis.com<\/a>\u00a0or follow Arcutis on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JbpFZo3ksboqvPC8agQEYZ_S9GrEfjMdcyLzfA--cAk1tQIUsEWM9QIaFb7GoxpARyC1qeOJU9cIm7GhdNXW-6S6tDrMGUyQeZZxJQKGtzVLZvRosQh0ET6-tbBBcNk7\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nbQAOZ6WFMToOPRHR77_5YhEgLJN1i3Vx3hX66HfIQNpz3tbp2w8MrgHvoVjK6su_LywNDMQ5BkVAIFUay2_WBVfH3fWHZKYVxB6L3F8ow4Cd4vCMhvxlWfpEFCta1oSZzU9HB-Kl7jJqCQHY9LnlQ==\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lVif4-UBa6NXMvOImSYbUYM6SeigeOGwMSbNGkv-NaQga8sjRyZ3XCM6V6xrGluYHR4t6ZdTwRT0udaeQ_rIOb4wmBDMshvcpS5EZ9_1o4o=\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZhgnwWrGX2p-7UiYpAzR_3qQWOFAUcXSyjK6ZaQNetCvf5mfVL9ryfEH2BG36tODy0BGNAAKTJaVYiRwmU54qA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>INDICATIONS<\/strong><br \/>\n        <br \/>ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.<\/p>\n<p>ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.<\/p>\n<p>ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.<\/p>\n<p>ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.<\/p>\n<p>ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.<\/p>\n<p>\n        <strong>IMPORTANT SAFETY INFORMATION <\/strong><br \/>\n        <br \/>ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).<\/p>\n<p>\n        <strong>Flammability:<\/strong> The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.<\/p>\n<p>The most common adverse reactions reported (\u22651%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).<\/p>\n<p>The most common adverse reactions reported (\u22651%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).<\/p>\n<p>The most common adverse reactions reported (\u22651%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).<\/p>\n<p>The most common adverse reactions reported (\u22651%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).<\/p>\n<p>The most common adverse reactions reported (\u22651%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).<\/p>\n<p>Please see full\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ywoSzRqalF8bP21tzniT0c54FtJALt73MbSWFJlQzeQYGehn9Ws8YDklaq0gKG95hmg77qNRZQWh2uVuDo7VA4zPUCXeJTikgBWc4leItqF5zndI7IDV--znjJHC7RW1TozJrYQjDjnLtLSRBt1ZGQe9P2R32cETwYkNpgUvCvRqS_xL6UHBQnVlM4SZqyRasE_QpGpTsd6ZL1tvs5WKq1pLvySmQVTZIWeDsQLfqbjidTXX6zL_7xpCLvaPobfkd6Cw4jsxGpHpC-Xte_yeuyetle-sxsV_uaHT-Fq2_gltawJq-rSN2RbBFOWG5bK9zLrlhYmU7kg-CkP7QpSFV7PDZZOXQOYbKdMNxnt7n1Y=\" rel=\"nofollow\" target=\"_blank\">Prescribing Information<\/a>\u00a0for ZORYVE cream and full\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ywoSzRqalF8bP21tzniT0c54FtJALt73MbSWFJlQzeTuFGTRkHDu3Eztai23TJnibBfbP86ivm6NEpn20v8bpWzEeGW6bC_E7Nhhw-EerMi0aMnQqkbh-09MSsl8RLxfWXHObonjMDGvpuppki13JDK4dTVEmlVfXC_0miPxN-xDt7z4aHwCm8AA-uCLS9lcavc0A1aNsR_nLEbEXdIfPaMNopUl7tneRewIDOJqt9rFqm6jpHOfnw0ale5vg3ClF21xmUKhQIFST6HWDVipPsDzE10e_Dy4QkWVZjqrciJ-X-Bw000tZOuAdHBkiGUlPIqHOTax7_KkrDRGDmXKKDT-kxAqUxYcMchOkBeVnYU=\" rel=\"nofollow\" target=\"_blank\">Prescribing Information<\/a>\u00a0for ZORYVE foam.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company\u2019s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential for investigational ZORYVE cream 0.05% to achieve the desired clinical trial results and to advance the standard of care in atopic dermatitis in infants aged 3\u2013&lt;24 months, and long-term use in children aged 2-5 years old, and the use of ZORYVE in seberrheic dermatitis and plaque psoriasis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the \u201cRisk Factors\u201d section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u>Media<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Amanda Sheldon, Head of Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jcCSDjNvqzaw23t2hrm1MfDdNJpuPw5QsE6f5mEL6l86gO3wFBbm1JIE8xN58sMcKm2e_Qs0m8RA7JU3KwbArsHMbWkKS0E4Afe5DtV8b6A=\" rel=\"nofollow\" target=\"_blank\">media@arcutis.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <em><br \/>\n            <u>Investors<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Brian Schoelkopf, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9mlhQNf8em9C7QncNLlbsH9vCZm83a-I7l5R8myrBpTB4eKQHjtSKWzzf0wTS6IsnXTdBN7vjWopXuttQksstQ==\" rel=\"nofollow\" target=\"_blank\">ir@arcutis.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWY4ZDM0YzctNmI4Ny00MWE2LTlkZmItNGRiOTAxNThlZTZjLTEyMDU2MDMtMjAyNi0wMy0xOC1lbg==\/tiny\/Arcutis-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE\u00ae (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting\u00a0taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, building on recently announced topline data. In addition, a five-minute poster presentation will highlight long-term caregiver-reported outcomes &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945304","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE\u00ae (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting\u00a0taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, building on recently announced topline data. In addition, a five-minute poster presentation will highlight long-term caregiver-reported outcomes &hellip; Continue reading &quot;Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T12:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting\",\"datePublished\":\"2026-03-18T12:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/\"},\"wordCount\":1337,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/\",\"name\":\"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=\",\"datePublished\":\"2026-03-18T12:05:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE\u00ae (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting\u00a0taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, building on recently announced topline data. In addition, a five-minute poster presentation will highlight long-term caregiver-reported outcomes &hellip; Continue reading \"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T12:05:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting","datePublished":"2026-03-18T12:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/"},"wordCount":1337,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/","name":"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=","datePublished":"2026-03-18T12:05:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEzNyM3NDkxMjAyIzIxOTQwNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945304"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945304\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}